Research Article| Volume 30, ISSUE 10, P1817-1830, October 2008

Download started.


Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose—block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study

      This paper is only available as a PDF. To read, Please Download here.


      Background: LC15-0444 is a selective inhibitor of dipeptidyl peptidase (DPP) IV under investigation in Korea for the treatment of type 2 diabetes.
      Objective: The aim of this study was to investigate the pharmacokinetic (PK), pharmacodynamic (PD), and tolerability profiles of a single dose of LC15-0444 in healthy male subjects.
      Methods: A dose—block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study was performed in healthy Korean male subjects assigned to receive 25, 50, 100, 200, 400, or 600 mg of LC15-0444 capsules. Blood and urine samples were collected up to 72 hours after administration. Plasma and urine drug concentrations were determined by tandem mass spectrometry coupled with high-performance liquid chromatography. DPP IV activity was measured by continuous spectrophotometric assay. An additional food effect study was performed in the 100-mg dose group; changes in PK and PD parameters after highfat diet were evaluated. Adverse events (AEs) were detected through investigator inquiries, spontaneous reports, and clinical evaluations such as physical examinations, vital sign measurements, 12-lead electrocardiography, clinical laboratory tests (eg, hematology, blood chemistry, coagulation, urinalysis), and computerized impedance cardiography.
      Results: Sixty Korean men (mean age, 25.3 years [range, 19-39 years]; weight, 68.3 kg [range, 53.6-84.9 kg]) were enrolled, providing 10 subjects for each dose group. After administration, LC15-0444 reached Tmax at 0.5 to 5.1 hours, and was eliminated with a t½ of 16.7 to 21.3 hours. The mean fraction of unchanged drug excreted in urine ranged from 0.21 to 0.34 and mean renal clearance was 15.5 to 23.6 L/h. The dose-normalized AUC exhibited dose-linearity over the range of 50 to 400 mg. All doses of LC15-0444 =200 mg were found to inhibit 80% of DPP IV activity for 24 hours. High-fat diet did not significantly influence the AUC of LC15-0444. LC15-0444 was generally well tolerated. None of the subjects developed any serious clinical or laboratory AEs or discontinued the study due to an AE. All AEs were mild or moderate, and no dose-related trends were observed. Fortysix AEs were reported in 18 subjects (30.0%). AEs considered to be related to the study drug were headache (6 cases), dizziness (2), nausea (1), epistaxis (1), and increased heart rate (1). All AEs resolved spontaneously.
      Conclusions: A single dose of LC15-0444 exhibited linear PK properties over the range of 50 to 400 mg in these healthy Korean male subjects. PK characteristics were not significantly influenced by food. In addition, doses ≥200 mg of LC15-0444 inhibited plasma DPP IV activity by >80% over a 24-hour dosing interval, and a 600-mg dose increased active glucagon-like peptide-1 levels after a standardized meal. LC15-0444 was generally well tolerated.

      Key words:

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Drucker DJ
        • Nauck MA
        The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
        Lancet. 2006; 368: 1696-1705
        • Flock G
        • Baggio LL
        • Longuet C
        • Drucker DJ
        Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.
        Diabetes. 2007; 56: 3006-3013
        • Ahren B
        • Simonsson E
        • Larsson H
        • et al.
        Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.
        Diabetes Care. 2002; 25: 869-875
        • Pei Z
        From the bench to the bedside: Dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
        Curr Opin Drug Discov Devel. 2008; 11: 512-532
      1. LG Life Sciences Ltd. (2007). Clinical Study Report. LGDPCL001. Seoul, Republic of Korea.

        • Kim D
        • Wang L
        • Beconi M
        • et al.
        (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
        J Med Chem. 2005; 48: 141-151
        • Schönberg L
        • Grobosch T
        • Lampe D
        • Kloft C
        Toxicological screening in urine: Comparison of two automated HPLC screening systems, toxicological identification system (TOX.I.S.*) versus REMEDI-HS.
        J Anal Toxicol. 2007; 31: 321-327
      2. (World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [WMA Web site]. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000) (Accessed)
        • Herman GA
        • Stevens C
        • Van Dyck K
        • et al.
        Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses.
        Clin Pharmacol Ther. 2005; 78: 675-688
        • Krikken JA
        • Lely AT
        • Bakker SJ
        • Navis G
        The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men.
        Kidney Int. 2007; 71: 260-265
        • Demuth HU
        • McIntosh CH
        • Pederson RA
        Type 2 diabetestherapy with dipeptidyl peptidase IV inhibitors.
        Biochim Biophys Acta. 2005; 1751: 33-44
        • Bergman AJ
        • Stevens C
        • Zhou Y
        • et al.
        Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A doubleblind, randomized, placebo-controlled study in healthy male volunteers.
        Clin Ther. 2006; 28: 55-72
        • Ritzel R
        • Orskov C
        • Holst JJ
        • Nauck MA
        Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
        Diabetologia. 1995; 38: 720-725
        • Woosley RL
        • Cossman J
        Drug development and the FDA's Critical Path Initiative.
        Clin Pharmacol Ther. 2007; 81: 129-133
        • Wagner JA
        • Williams SA
        • Webster CJ
        Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs.
        Clin Pharmacol Ther. 2007; 81: 104-107
        • Herman GA
        • Stein PP
        • Thornberry NA
        • Wagner JA
        Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin.
        Clin Pharmacol Ther. 2007; 81: 761-767
        • Herman GA
        • Bergman A
        • Liu F
        • et al.
        Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
        J Clin Pharmacol. 2006; 46: 876-886